{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/6a7de7c2ff328abd8427c196?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris","description":"<p>Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant <em>Candida auris</em> was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.</p><p><br></p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news.&nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>: </p><p><a href=\"https://www.genengnews.com/topics/bioprocessing/bms-chooses-houston-for-2-3b-manufacturing-facility/\" rel=\"noopener noreferrer\" target=\"_blank\">BMS Chooses Houston for $2.3B Manufacturing Facility</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, Aug 10, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/next-10-u-s-biopharma-clusters/?_gl=1*1am4j3p*_up*MQ..*_ga*MTIxNjk5MDgwMS4xNzYwNTUyNDU2*_ga_F1EYPPYL3X*czE3ODY1NTcwMDUkbzEkZzAkdDE3ODY1NTgyODYkajQyJGwwJGgxMDA3NTk4Njgw\" rel=\"noopener noreferrer\" target=\"_blank\">Next 10 U.S. Biopharma Clusters</a></p><p>By Alex Philippidis, <em>GEN</em>, Aug 12, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/recursion-partners-with-genentech-to-advance-first-validated-neuro-target-discovered-through-ai-map/\" rel=\"noopener noreferrer\" target=\"_blank\">Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, Aug 5, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/coronavirus/covid-19-reactivates-dormant-viruses-offering-new-clues-to-long-covid/\" rel=\"noopener noreferrer\" target=\"_blank\">COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID</a></p><p><em>GEN</em>, Aug 5, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/insights/trumps-treatments-regenerons-antibodies-and-gileads-remdesivir-explained/\" rel=\"noopener noreferrer\" target=\"_blank\">Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained</a></p><p>By Alex Philippidis, <em>GEN</em>, Oct 5, 2020</p><p><br></p><p><a href=\"https://www.genengnews.com/gen-edge/lessons-from-the-covid-crisis-an-interview-with-peter-hotez/\" rel=\"noopener noreferrer\" target=\"_blank\">Lessons from the COVID Crisis: An Interview with Peter Hotez</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, Oct 19, 2022</p><p><br></p><p><a href=\"https://www.genengnews.com/a-lists/how-to-conquer-coronavirus-top-35-treatments-in-development/\" rel=\"noopener noreferrer\" target=\"_blank\">How to Conquer Coronavirus: Top 35 Treatments in Development</a></p><p>By Alex Philippidis, <em>GEN</em>, March 2, 2020</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/infectious-diseases/candida-auris-persists-in-hair-follicles-hijacks-immune-signaling/\" rel=\"noopener noreferrer\" target=\"_blank\">Candida auris Persists in Hair Follicles, Hijacks Immune Signaling</a></p><p><em>GEN</em>, August 10, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/multimedia/summits/the-state-of-biotech-2026/\" rel=\"noopener noreferrer\" target=\"_blank\">The State of Biotech Summit</a></p><p>September 23, 2026</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a>&nbsp;</p><p>Hosted by Corinna Singleman, PhD&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a>&nbsp;</p><p>Hosted by Jonathan D. Grinstein, PhD&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/resources/the-state-of-biologics-testing-2026/\" rel=\"noopener noreferrer\" target=\"_blank\">The State of Biologics Testing 2026</a></p><p>Charles River Laboratories and <em>GEN</em>, June 10, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/newsletter-sign-up/?_gl=1*1of46um*_up*MQ..*_ga*MTIxNjk5MDgwMS4xNzYwNTUyNDU2*_ga_F1EYPPYL3X*czE3ODY2MDMzMzckbzEkZzAkdDE3ODY2MDMzMzckajYwJGwwJGgxMjE3MTEyMTkx\" rel=\"noopener noreferrer\" target=\"_blank\">Subscribe to <em>GEN</em>’s newsletters</a></p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}